ストックスクリーナーアプリを入手
6.81
2.58%
-0.18
アフターアワーズ：
6.80
-0.010
-0.15%
Kyverna Therapeutics Inc (KYTX) 最新ニュース
Kyverna's miv-cel shows durable one-year benefit in stiff person syndrome and myasthenia gravis - The Pharma Letter
H.C. Wainwright reiterates Kyverna stock rating on durability data By Investing.com - Investing.com Nigeria
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG TrialsSlideshow (NASDAQ:KYTX) 2026-09-24 - Seeking Alpha
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price - TradingView
Kyverna Therapeutics Therapy Delivers Sustained Relief in Rare Neurological Conditions - Benzinga
Kyverna Shooting for Complete BLA Submission for Stiff Person Syndrome CAR T-Cell Therapy This Year - GenomeWeb
Kyverna stock jumps on positive one-year therapy data By Investing.com - Investing.com Canada
Kyverna stock jumps on positive one-year therapy data - Yahoo Finance
Kyverna’s Miv-cel Holds One-Year Benefit in Stiff Person Syndrome - Minichart
KYTX: Miv-cel delivers durable, drug-free remissions in SPS and gMG with a strong safety profile - TradingView
William Blair Initiates Kyverna Therapeutics(KYTX.US) With Buy Rating - Moomoo
Form 8K Kyverna Therapeutics Inc For: 24 September By Investing.com - Investing.com Nigeria
Why is Kyverna Therapeutics stock surging today? By Investing.com - Investing.com Canada
Kyverna Reports One-Year Miv-Cel Data From SPS and gMG Trials - Yahoo Finance
Kyverna reports one-year data for autoimmune CAR T therapy - Investing.com
Kyverna reports one-year data for autoimmune CAR T therapy By Investing.com - Investing.com Canada
Kyverna Therapeutics Reports Durable One-Year SPS and Up to 1.5-Year gMG Data for Miv-Cel - Quiver Quantitative
Kyverna Therapeutics reports positive one-year miv-cel data in SPS; rolling BLA on track for Q4 - TradingView
Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T - Endpoints News
Electra's IPO Break, Three CAR-T Deaths, and a Tariff Deadline Nobody Understands - finance.biggo.com
KYTX: Miv-cel shows transformative results in SPS and gMG, with regulatory and commercial milestones ahead - TradingView
Kyverna Therapeutics aims for first approved ce... - Pluang
Kyverna at Morgan Stanley healthcare conference: first autoimmune CAR T launch - Investing.com Australia
Kyverna at wells fargo healthcare conference: autoimmune car t push advances - Investing.com Canada
KYTX: Miv-cel shows unprecedented efficacy in SPS, with regulatory and commercial milestones set for 2027 - TradingView
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
BlackRock Inc. Purchases Shares of 3,134,807 Kyverna Therapeutics, Inc. $KYTX - MarketBeat
Kyverna Therapeutics (KYTX) Slips 3.08% to $8.35 as Clinical-Stage Biotech Faces Selling PressureElliott Wave Entry - dars.gov.et
Wells Fargo Keeps Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX) - The Globe and Mail
Kyverna Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts - BioPharma Dive
Wells Fargo Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Kyverna (KYTX): Posts a 3.09% Loss to $8.16 at the Close; Chart Watch: the Session Ends Within the Reported Technical Boundaries in the Latest SessionTime Weighted Price - dars.gov.et
Kyverna Therapeutics (NASDAQ:KYTX) Trading Down 7.3%Time to Sell? - MarketBeat
Miv-cel Earns RMAT Designation for Progressive Multiple Sclerosis - CGTLive®
Kyverna (KYTX) Latest Reading: Declines 5.03% to $8.50 in the Latest Session; Session Range View: the Session Ends Within the Reported Technical Boundaries in the Available RecordDay Trade Opportunities - vinanet.vn
Kyverna Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
KYTX Stock Soars After Hours: What’s Driving The Rally? - Stocktwits
Kyverna Therapeutics (NASDAQ:KYTX) Trading 6.7% HigherShould You Buy? - MarketBeat
AIGH Capital Management LLC Purchases Shares of 2,795,797 Kyverna Therapeutics, Inc. $KYTX - MarketBeat
Walleye Capital LLC Purchases New Shares in Kyverna Therapeutics, Inc. $KYTX - MarketBeat
KYTX Edges Higher: Kyverna Therapeutics Climbs 1.11% to $8.17Fibonacci Retracement - Vinanet
Q3 EPS Estimate for Kyverna Therapeutics Lifted by Analyst - MarketBeat
Kyverna Therapeutics (KYTX): Bain Capital fund reports 4.75% ownership stake - Stock Titan
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
KYTX Q1 2026 Earnings: Narrower-than-Expected Loss of -0.66 per Share Highlights Clinical-Stage Cost Discipline - vinanet.vn
Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval (NASDAQ:KYTX) - Seeking Alpha
H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Kyverna Therapeutics (KYTX) Earnings Date and Reports 2026 $KYTX - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Releases Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Kyverna Therapeutics narrows Q2 losses, secures RMAT for miv-cel - scanx.trade
Kyverna Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Kyverna Therapeutics Announces Q2 2026 Financial Results and Operational Update - Kalkine Media
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results - The Manila Times
KYTX: Q2 2026 net loss narrowed to $38.3M as miv-cel advanced toward commercialization - TradingView
Kyverna Therapeutics (KYTX) deepens pipeline with SPS BLA, H1 2026 loss narrows - Stock Titan
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):